Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

Described are immunotherapeutic combinations that are used to impede the growth of tumour cells and/or to eliminate those cells. The method can be used to observe a therapeutic antitumour effect by combining idiotypic vaccines having an antiganglioside antibody (Ab1) as the active principle thereof...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DIAZ RODRIGUEZ, YILDIAN, VAZQUEZ LOPEZ, ANA MARIA, FERNANDEZ MOLINA, LUIS ENRIQUE, PEREZ GONZALEZ, ALEXIS, ARR PEREZ, ADRIANA, ALFONSO FERNANDEZ, MAURO A, PEREZ RODRIGUEZ, ROLANDO
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Described are immunotherapeutic combinations that are used to impede the growth of tumour cells and/or to eliminate those cells. The method can be used to observe a therapeutic antitumour effect by combining idiotypic vaccines having an antiganglioside antibody (Ab1) as the active principle thereof with idiotypic vaccines, the active principle of which is an anti-idiotypic antibody obtained against an antiganglioside antibody (Ab2), or with vaccines, the active principle of which is one or more gangliosides. Also described are combinations of vaccines which produce a synergism of the antitumour effect, which is induced separately by each of the vaccines. The combinations can be applied to patients in different clinical states with tumours that overexpress gangliosides.